Cargando…

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

We recently discovered mutation signatures reminiscent of BRCA deficiency in the vast majority of a set of primary osteosarcomas (OS). In the current study, we therefore investigated the sensitivity of a panel of OS cell lines to the poly(ADP)-ribose polymerase (PARP) inhibitor talazoparib alone and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engert, Florian, Kovac, Michal, Baumhoer, Daniel, Nathrath, Michaela, Fulda, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564725/ https://www.ncbi.nlm.nih.gov/pubmed/27447864 http://dx.doi.org/10.18632/oncotarget.10720

Ejemplares similares

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma
por: Barenboim, Maxim, et al.
Publicado: (2021)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
por: Kovac, Michal, et al.
Publicado: (2015)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
por: Ameline, Baptiste, et al.
Publicado: (2020)

NTRK fusions in osteosarcoma are rare and non‐functional events
por: Ameline, Baptiste, et al.
Publicado: (2020)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation
por: Poos, Kathrin, et al.
Publicado: (2014)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies
por: Kovac, Michal, et al.
Publicado: (2021)

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
por: Li, Hongyi, et al.
Publicado: (2020)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

How MicroRNA and Transcription Factor Co-regulatory Networks Affect Osteosarcoma Cell Proliferation
por: Poos, Kathrin, et al.
Publicado: (2013)

Genomic Heterogeneity of Osteosarcoma - Shift from Single Candidates to Functional Modules
por: Poos, Kathrin, et al.
Publicado: (2015)

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
por: Heidler, Christopher L., et al.
Publicado: (2019)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

New Small Molecules Targeting Apoptosis and Cell Viability in Osteosarcoma
por: Maugg, Doris, et al.
Publicado: (2015)

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
por: Darbeheshti, Farzaneh, et al.
Publicado: (2022)

Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma – reasons and consequences
por: Arabi, Leila, et al.
Publicado: (2014)

The long non-coding RNA PARTICLE is associated with WWOX and the absence of FRA16D breakage in osteosarcoma patients
por: O'Leary, Valerie Bríd, et al.
Publicado: (2017)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample
por: Yoshida, Reiko, et al.
Publicado: (2021)

Solitary pulmonary metastases at first recurrence of osteosarcoma: Presentation, treatment, and survival of 219 patients of the Cooperative Osteosarcoma Study Group
por: Mettmann, Vanessa L., et al.
Publicado: (2023)

CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients
por: Baumhoer, Daniel, et al.
Publicado: (2011)

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
por: Zhang, Di, et al.
Publicado: (2021)

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
por: Naito, Yoichi, et al.
Publicado: (2021)

Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation
por: Lesueur, Paul, et al.
Publicado: (2018)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_41joohc28nlmd5u1e6olfv9tb4